Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positive developments in clinical trials and partnerships, there are risks associated with trial outcomes and partnership dependencies. Financials show reduced R&D expenses, but operating expenses remain high, and cash position is stable. The Q&A reveals interest in IPH4502 and MATISSE programs, but management's lack of clarity on certain details introduces uncertainty. Overall, the sentiment is balanced by positive clinical progress and financial stability, offset by risks and unclear guidance, suggesting a neutral stock price reaction in the short term.
Key Financial Performance
Revenue and Other Income EUR 9 million for 2025, including EUR 2.8 million from licensing and collaboration agreements and EUR 6.2 million in governmental funding for research expenditures.
Operating Expenses EUR 63 million in 2025, with 73% related to R&D. R&D expenses were EUR 43.6 million, a 16% decrease year-over-year due to study maturity, lower staff costs, and reduced scientific consulting and IP costs, partially offset by restructuring charges.
G&A Expenses EUR 19.4 million in 2025, broadly stable year-over-year, with decreases in nonscientific consulting fees and insurance expenses, partially offset by restructuring plan impacts.
Cash Position EUR 44.8 million as of December 31, 2025, providing funding visibility until the end of Q3 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IPH4502: Progressing in Phase I with observed preliminary antitumor activity and favorable safety profile, particularly in patients with urothelial cancer relapsed or refractory to EV. Potential to address unmet needs in post-PADCEV setting and expand to low/moderate Nectin-4 expressing tumors.
Lacutamab: Preparing for Phase III TELLOMAK-3 study initiation in 2026. Demonstrated clinically meaningful activity in Phase II for Sezary Syndrome and Mycosis Fungoides. Regulatory designations obtained include Breakthrough Therapy and Orphan Drug Designation. Potential market opportunity of $150M in Sezary Syndrome, expanding to $500M across broader CTCL market.
Monalizumab: Phase III PACIFIC-9 trial in non-small cell lung cancer completed enrollment. Data expected in the second half of 2026. Represents a late-stage asset with potential for significant impact.
CTCL Market (Lacutamab): Sezary Syndrome market opportunity estimated at $150M, expanding to $500M with Mycosis Fungoides. Mogamulizumab sales provide a benchmark, reaching $300M in 2025 and projected $350M in 2026.
Strategic Focus: Prioritized investment in three key assets: IPH4502, lacutamab, and monalizumab. Streamlined organization with redundancy plan to enhance agility and capital allocation.
Financial Position: Cash position of EUR 44.8M as of 2025-end, providing funding visibility until Q3 2026. Revenue of EUR 9M in 2025, with 73% of operating expenses allocated to R&D.
Partnerships and Financing: Ongoing negotiations for non-dilutive financing options, including pharma partnerships and royalty-based structures, to support late-stage development.
Pipeline Development: Focused on advancing three high-value assets with clear milestones and catalysts, including Phase III trials and regulatory approvals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Strategic Focus and Resource Allocation: The company has prioritized investment in three clinical assets (IPH4502, lacutamab, and monalizumab), which may limit resources for other potential opportunities. Additionally, the redundancy plan and organizational streamlining could pose risks to operational efficiency and employee morale.
Regulatory and Clinical Development Timelines: The initiation of the TELLOMAK-3 Phase III trial for lacutamab is delayed until the second half of 2026, contingent on financing options. This delay could impact the company's ability to achieve timely regulatory approvals and market entry.
Financial Constraints: The company has a cash position of EUR 44.8 million, providing funding visibility only until the end of Q3 2026. This creates a risk of financial shortfall if additional funding or partnerships are not secured.
Market Competition and Adoption: IPH4502 and lacutamab face competitive pressures from existing therapies like enfortumab vedotin and mogamulizumab. Capturing market share in these segments will require demonstrating clear clinical and commercial advantages.
Clinical Trial Risks: The success of IPH4502 and monalizumab depends on ongoing clinical trials, including the PACIFIC-9 Phase III trial. Any unfavorable trial outcomes could significantly impact the company's strategic objectives.
Dependence on Partnerships: The company relies heavily on partnerships with AstraZeneca and others for the development and commercialization of key assets. Any changes or disruptions in these partnerships could adversely affect progress.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Initiation of TELLOMAK-3 Phase III trial: The TELLOMAK-3 Phase III trial with lacutamab in CTCL is expected to be initiated in the second half of 2026, following FDA clearance.
Monalizumab PACIFIC-9 Phase III trial: The PACIFIC-9 Phase III trial data readout for monalizumab in non-small cell lung cancer is expected in the second half of 2026.
IPH4502 Phase I trial: IPH4502 is progressing in Phase I trials with observed preliminary antitumor activity and a favorable safety profile. The focus is on patients with urothelial cancer relapsed or refractory to enfortumab vedotin, with potential expansion into earlier lines of therapy and additional tumor types.
Regulatory timelines for lacutamab: The TELLOMAK-3 study is designed to serve as a confirmatory trial for Sezary Syndrome and support full approval in Mycosis Fungoides. Accelerated approval for Sezary Syndrome is possible once the Phase III trial is underway.
Commercial strategy for lacutamab: Lacutamab's initial market opportunity is estimated at up to $150 million in Sezary Syndrome, expanding to over $500 million across Sezary and Mycosis Fungoides in the second-line setting, with additional upside in earlier lines of therapy.
IPH4502 development strategy: IPH4502 aims to address unmet needs in the post-enfortumab vedotin setting for urothelial cancer and expand into earlier lines of therapy and other tumor types with low to moderate Nectin-4 expression.
Funding visibility: The company has funding visibility until the end of the third quarter of 2026, based on its current operating plan.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide additional specifics regarding the IPH4502 program and its competitive positioning?
A:The IPH4502 program is progressing well with significant interest. The program focuses on the post-PADCEV setting as a TOPO1 ADC, which differentiates it from MMAE-based ADCs. Preliminary antitumor activity has been observed, and the MTD has been established at expected levels. The program shows encouraging activity at therapeutic doses across different tumor types.
Q:What should we expect from the MATISSE interim data presentation at AACR?
A:The MATISSE trial, in collaboration with AstraZeneca, aims to validate the target and explore development in lung cancer. The interim analysis will present data from the first 40 patients out of 70. The trial design was previously disclosed, and the data is embargoed until the AACR meeting.
Q:Why has collaboration revenue from the monalizumab program dropped, and are additional milestones expected?
A:The revenue drop is due to the completion of obligations under the old agreement. The project is now fully managed by AstraZeneca, and future developments depend on upcoming results expected in the second half of the year.
Q:What were the key takeaways from the Phase I data of the MATISSE program, and why did AstraZeneca move it to the early-stage setting?
A:Phase I data showed that the dose used effectively blocked CD39 enzymatic activity in patients. This finding, along with the expression of CD39 in early lung cancer, supports the move to the early-stage setting to test the combination's efficacy.
Q:How does CD39 fit in relation to CD73, and is CD39 alone sufficient to block adenosine inhibition?
A:CD39 is upstream in the ATP degradation pathway, while CD73 is downstream. Blocking CD39 prevents ATP degradation and limits adenosine accumulation, which is immune-stimulating. This makes CD39 blockade particularly effective when combined with apoptosis inducers like chemotherapy.
Q:What updates can you share about lacutamab partnership discussions and potential deal structures?
A:The company is evaluating both BD partnerships and royalty financing options to bring lacutamab to market quickly. The decision will focus on maximizing long-term shareholder value, with timelines for approval being similar for both options.
Q:What can we expect from the initial update on IPH4502, and has antitumor activity been observed in other tumor types?
A:The program has shown antitumor activity in post-EV and other tumor types. The focus is on safety, PK, free payload levels, and efficacy readouts, including Nectin-4 expression. Data will be presented at a medical conference once matured.
Q:What can we expect from the ADC data readouts, and what sales infrastructure is planned for lacutamab?
A:The ADC data readouts will focus on safety, PK, free payload levels, and efficacy, including Nectin-4 expression. For lacutamab, if commercialized independently, a small sales infrastructure of around 20 salespeople, 5-6 medical affairs staff, and a few access personnel would be required.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the clinical activity of IPH4502 in other tumor types, citing the ongoing nature of the trial. Additionally, they did not disclose specifics about the lacutamab partnership decision timeline or the exact data to be presented at the AACR meeting for MATISSE.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Cohort patient
Commercial
Designation
EUR
EV treatment
FDA clearance
IPH antitumor
IPH potential
MF
MMAE
Nectin ADCs
Officer Slide
PACIFIC trial
Phase II
SS line
Slide IPH
TELLOMAK study
TOPO
agreement
analysis
antitumor activity
approach
class
durvalumab
endpoint
expression IPH
funding
limitation
line setting
line therapy
majority
market
mechanism
mogamulizumab
monalizumab IPH
parallel
population
profile IPH
progression
royalty
sale
survival
treatment landscape
world
IPHA Transcript
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Unknown3-26
The earnings call presents a mixed picture. While there are positive developments in clinical trials and partnerships, there are risks associated with trial outcomes and partnership dependencies. Financials show reduced R&D expenses, but operating expenses remain high, and cash position is stable. The Q&A reveals interest in IPH4502 and MATISSE programs, but management's lack of clarity on certain details introduces uncertainty. Overall, the sentiment is balanced by positive clinical progress and financial stability, offset by risks and unclear guidance, suggesting a neutral stock price reaction in the short term.
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed outlook: strong financial metrics with a cash runway through Q3 2026, positive trial progress, and potential for accelerated approval of Lacutamab. However, uncertainties remain due to potential supply chain issues in ADCs, lack of clear guidance on partnerships, and management's vague responses on future plans. The neutral sentiment reflects balanced positive and negative factors, with no strong catalysts to move the stock significantly.
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Unknown9-17
The earnings call highlighted several concerns: financial constraints with a limited cash runway, significant operating expenses, and dependency on a few key programs. While there were collaborations with major companies, the lack of diversification and potential regulatory hurdles for key drugs add risks. The Q&A revealed uncertainties about strategic refocus and financial impacts, with management avoiding specific answers, raising investor concerns. Overall, the company's challenges and lack of clear positive catalysts suggest a negative stock price movement.
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call reveals mixed signals. The strategic investment from Sanofi is positive, indicating confidence in Innate's platforms, and suggests potential growth. However, the company faces significant regulatory, competitive, and supply chain risks. Additionally, the management's reluctance to provide clear guidance, particularly concerning IPH6101, raises concerns. The cash position is stable, but the absence of Phase 3 funding for lacutamab is a drawback. Overall, these factors balance out, resulting in a neutral sentiment.
IPHA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
